# CALGB 80802 (NCT01015833)

> Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

No report yet. It can be ordered.

- Drugs tested: sorafenib plus doxorubicin
- Indication: advanced hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01015833
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Advanced Adult Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Unresectable Hepatocellular Carcinoma
- Interventions: Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Pharmacogenomic Study; Sorafenib Tosylate
- Enrollment: 356
- Primary outcome: Overall Survival

## Indexed commentary on CALGB 80802 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=calgb-80802-nct01015833